Asinex Corporation

What Asinex Corporation does

Asinex Corporation is a privately-held drug discovery chemistry company founded in 1994 and headquartered in Winston-Salem, North Carolina, with a European global headquarters in Amsterdam, the Netherlands. The company designs and synthesizes commercial screening libraries and chemical building blocks used by pharmaceutical companies, biotechnology firms, and academic institutions for hit identification, hit-to-lead, and lead optimization. Its product portfolio spans three layers: (1) screening libraries — including the Synergy 2.0 on-demand synthesis platform (1,000,000 enumerated compounds integrating Diversity-Oriented Synthesis, High-Throughput Experimentation, and Machine Learning), pre-plated phenotypic sets, and ultra-large virtual libraries of over 1 trillion synthetically feasible molecules; (2) specialized chemotypes — α-helix mimetics, cell-permeable macrocycles, glycomimetics, peptidomimetics, nucleoside mimetics, and soft electrophiles/covalent fragments; and (3) PROTAC and molecular glue components — E3 ligase ligands, 100+ linkers, E3-linker conjugates, and a 1,368-compound molecular glue library. The firm also supplies building blocks and polyfunctional macrocyclic intermediates (MacroDEL) for DNA-encoded library synthesis, plus research-area-focused collections covering RNA-binding, kinase, PPI, oncology, immuno-oncology, ion channels, CNS, and antibacterial/antiviral targets.

Asinex generates revenue through a combination of one-time catalog sales (via a self-serve eShop for cherry-picking and bulk purchase) and professional services revenue from custom synthesis and on-demand library production. Pricing is quote-based and not publicly disclosed. The go-to-market is sales-led, with direct field sales through the two regional offices handling custom and larger orders, supplemented by e-commerce for standard catalog items and by scientific publications and conference participation for top-of-funnel awareness. The company operates with a lean management team — founder Dmitry Genis (CEO), Mark Parisi (Executive Director, North America), Ludmila Sadovenko (Director of Marketing Strategy, Europe), and Dr. Roman Kombarov (Head of Business Development) — and has maintained continuous operation since founding without disclosed external funding rounds or institutional investors.

Name

Asinex Corporation

Legal name

Asinex Corporation

Website

https://asinex.com

Company type

Private

Founded year

1994

Operating status

Operating

Short description

Asinex Corporation is a privately-held drug discovery chemistry company founded in 1994 that designs and synthesizes commercial screening libraries, macrocycles, PROTAC components, and DNA-encoded library building blocks for pharmaceutical, biotechnology, and academic customers via catalog sales and custom synthesis services.

Ownership category

akta.pro rank

Product category

Drug Discovery Chemistry

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)

Keywords

• Screening libraries
• Drug discovery chemistry
• Macrocycles drug discovery
• PROTAC building blocks
• DNA-encoded libraries

Headquarters

HQ city

Winston Salem

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain

Revenue model

1. Screening Library Sales: Sale of pre-designed compound libraries including screening libraries, pre-plated sets, building blocks, and fragments. Products available via eShop for cherry-picking or bulk purchase.
2. Custom Synthesis Services: On-demand synthesis services including Synergy 2.0 library (1M compounds), custom PROTAC components, and specialized macrocyclic compounds. Scalable synthesis protocols for hit-to-lead optimization.
3. DEL Building Blocks: Sale of DNA-encoded library building blocks including macrocyclic intermediates and polyfunctional monomers for DEL research

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Asinex Corporation designs, synthesizes, and sells compound screening libraries, building blocks, fragments, macrocycles, and PROTAC components for drug discovery researchers in pharmaceutical, biotechnology, and academic organizations. The company also offers custom chemistry services, including targeted library design, hit confirmation, hit-to-lead, lead optimization, and on-demand combinatorial synthesis through its Synergy 2.0 platform. Products are delivered as physical compound samples, pre-plated sets in 96-well formats, and downloadable SDF structure files.

Product overview

Asinex Corporation is a drug discovery chemistry company offering a comprehensive portfolio of screening libraries and custom synthesis services. The core offering consists of three main categories: (1) Screening Libraries including the flagship Synergy 2.0 on-demand synthesis platform (1M compounds), all-purpose screening collections, and pre-plated phenotypic sets; (2) Specialized ChemoTypes including α-helix mimetics, macrocycles, glycomimetics, peptidomimetics, nucleoside mimetics, and soft electrophiles; and (3) PROTAC/Molecular Glue components including E3 Ligase Ligands, Linkers (100+), E3-Linker Conjugates, and Molecular Glues. The company also provides Building Blocks for both traditional and DNA-encoded library (DEL) synthesis, including MacroDEL intermediates and Speed Chemistry Building Blocks. Research area-focused libraries cover RNA-Binding, Kinases, Protein-Protein Interactions, Targeted Oncology, Immuno-Oncology, Ion-Channels, Signal Pathways, CNS, Epigenetics, GPCR, Antibacterial, and Antiviral targets. The portfolio serves pharmaceutical and biotech companies through on-demand synthesis, cherry-picking, and pre-plated formats.

Differentiator

Problem solved

Functional benefit

Products and services

• Asinex Screening Libraries (Overall Catalog) A broad catalog of screening compound libraries covering diverse chemotypes and small molecules for hit identification and lead discovery, sold to pharmaceutical, biotechnology, and academic drug discovery teams.
• Synergy 2.0 A custom combinatorial chemistry service that delivers designed libraries on demand by combining solution-phase and solid-phase parallel synthesis, used by drug discovery teams needing targeted analog sets.
• Speed Chemistry Building Blocks A collection of more than 60,000 building blocks designed to enable rapid hit confirmation and SAR exploration for medicinal chemists running hit-to-lead and lead optimization campaigns.
• Building Blocks for DEL (DNA-Encoded Libraries) A collection of building blocks specifically designed and pre-validated for DNA-encoded library construction, sold to researchers running DEL screening campaigns.
• MacroDEL (Macrocyclic Intermediates for DEL) Macrocyclic intermediates designed and pre-validated for use in DNA-encoded library construction and screening, enabling macrocycle-based DEL campaigns.
• Macrocyclic Compound Libraries A family of macrocyclic compound libraries sold to drug discovery researchers working on macrocycle-based therapeutics across multiple chemotypes.
• Glycomimetic Macrocycles Macrocyclic libraries designed as glycomimetic scaffolds targeting carbohydrate-binding proteins and related drug discovery targets.
• Peptidic Macrocycles (Peptidomimetics) Peptidic macrocycle libraries (peptidomimetics) for drug discovery programs targeting challenging interfaces such as protein-protein interactions.
• Nucleoside Mimetics Nucleoside mimetic compound collections used to support antiviral and nucleic acid-related drug discovery efforts.
• Soft Electrophiles Soft electrophile collections designed for targeted covalent inhibitor discovery and related covalent drug discovery campaigns.
• α-Helix Mimetics α-Helix mimetic libraries designed to disrupt protein-protein interactions mediated by α-helical recognition motifs.
• Covalent Fragments Fragment-sized compounds designed to covalently engage Cys, Lys, and other target residues, used in covalent fragment screening campaigns.
• Covalent Library Ready to Dock A docking-ready covalent library covering more than 40 electrophilic classes with diverse ligand structures, used for computational docking and screening of covalent inhibitors.
• Protein Degraders (PROTAC Components) A catalog of building blocks for assembling PROTACs and other targeted protein degraders, used by drug discovery teams running targeted protein degradation programs.
• E3 Ligase Ligands Building blocks representing E3 ligase ligands, used as one half of PROTAC or targeted protein degrader constructs in protein degradation drug discovery.
• Linkers Linker building blocks used to connect warhead and E3 ligase ligand components in PROTAC and other bifunctional molecule design.
• E3-Linker Conjugates Pre-assembled E3-linker conjugate building blocks that simplify PROTAC synthesis by providing ready-to-couple E3 ligase recruiting units for degrader programs.
• Molecular Glues Building blocks for molecular glue degraders and other induced proximity approaches in targeted protein degradation drug discovery.
• Kinase Library A target-class screening library of more than 9,000 small molecules for kinase drug discovery programs.
• Protein-Protein Interaction (PPI) Libraries

Quantifiable outcome

• Delivers tractable hits for drug discovery projects with optimized ADMET and PK properties
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature7 records

Partnerships

One partnership is on record.

• BioSolveITnotableTechnology or Integration · 20 September 2021Collaboration resulted in a 50K covalent compound set conveniently processed for SeeSAR molecular modeling software by BioSolveIT. The molecules are available for purchase from Asinex through their on-line search engine.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Market position

Strengths4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Asinex Corporation